All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ramucirumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4917	947687-13-0

Description:

Molecule

Description

Synonyms: ramucirumab cyramza IMC-1121B

Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
40	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
March 26, 2015	PMDA	Eli Lilly Japan K.K.
Dec. 19, 2014	EMA	Eli Lilly Nederland B.V.
April 21, 2014	FDA	ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	378.63	38.74	132	2322	106738	90519255
Ascites	138.23	38.74	51	2403	47689	90578304
Disease progression	111.95	38.74	63	2391	156552	90469441
Nephrotic syndrome	101.06	38.74	26	2428	7313	90618680
Neutropenia	88.61	38.74	62	2392	224842	90401151
Proteinuria	71.46	38.74	26	2428	23265	90602728
Death	60.93	38.74	68	2386	456483	90169510
Neuropathy peripheral	59.11	38.74	40	2414	136930	90489063
Haemoptysis	55.75	38.74	24	2430	33296	90592697
Neutrophil count decreased	54.30	38.74	30	2424	71502	90554491
Chylothorax	50.49	38.74	9	2445	440	90625553
Gastrointestinal perforation	48.36	38.74	13	2441	4319	90621674
Pyogenic granuloma	46.47	38.74	8	2446	319	90625674
Anaemia	39.35	38.74	48	2406	352754	90273239

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	511.00	28.72	243	4372	108157	42508563
Disease progression	104.30	28.72	101	4514	143555	42473165
Interstitial lung disease	103.96	28.72	78	4537	78384	42538336
Febrile neutropenia	91.12	28.72	106	4509	185597	42431123
Neutrophil count decreased	77.24	28.72	60	4555	63355	42553365
Neutropenia	77.10	28.72	101	4514	199330	42417390
Decreased appetite	73.38	28.72	97	4518	193040	42423680
Gastric perforation	66.29	28.72	21	4594	3072	42613648
Tumour haemorrhage	62.94	28.72	21	4594	3617	42613103
Proteinuria	60.13	28.72	35	4580	22948	42593772
Neuropathy peripheral	59.87	28.72	64	4551	101789	42514931
Ascites	59.13	28.72	49	4566	56629	42560091
Metastases to liver	51.19	28.72	28	4587	16298	42600422
Fulminant type 1 diabetes mellitus	45.28	28.72	13	4602	1361	42615359
Pneumonitis	39.24	28.72	34	4581	41684	42575036
Peritonitis	37.50	28.72	24	4591	18609	42598111
Death	34.18	28.72	120	4495	471065	42145655
Therapy partial responder	31.19	28.72	22	4593	19999	42596721
Recall phenomenon	30.37	28.72	8	4607	608	42616112
Nephrotic syndrome	30.25	28.72	16	4599	8702	42608018
Stomatitis	30.17	28.72	32	4583	50297	42566423
Metastases to lung	28.81	28.72	17	4598	11407	42605313

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	776.64	30.09	318	6498	174249	110408234
Disease progression	244.50	30.09	164	6652	243870	110338613
Ascites	186.77	30.09	98	6718	92710	110489773
Neutropenia	160.67	30.09	153	6663	374467	110208016
Interstitial lung disease	152.23	30.09	99	6717	139235	110443248
Neutrophil count decreased	137.17	30.09	88	6728	120853	110461630
Febrile neutropenia	129.31	30.09	126	6690	316641	110265842
Proteinuria	127.84	30.09	58	6758	39960	110542523
Neuropathy peripheral	116.66	30.09	93	6723	179184	110403299
Nephrotic syndrome	107.25	30.09	38	6778	13793	110568690
Tumour haemorrhage	101.78	30.09	29	6787	5216	110577267
Decreased appetite	96.67	30.09	132	6684	475714	110106769
Gastric perforation	81.21	30.09	24	6792	4905	110577578
Pyogenic granuloma	70.56	30.09	14	6802	529	110581954
Peritonitis	67.10	30.09	35	6781	32572	110549911
Therapy partial responder	65.64	30.09	36	6780	37025	110545458
Gastrointestinal perforation	55.95	30.09	20	6796	7436	110575047
Death	52.83	30.09	126	6690	698743	109883740
Polyneuropathy	50.97	30.09	29	6787	31983	110550500
Pneumonitis	50.32	30.09	40	6776	76491	110505992
Fulminant type 1 diabetes mellitus	50.08	30.09	14	6802	2349	110580134
Chylothorax	49.60	30.09	12	6804	1144	110581339
Metastases to liver	43.16	30.09	27	6789	35359	110547124
Epistaxis	38.95	30.09	44	6772	130328	110452155
Metastases to peritoneum	38.17	30.09	14	6802	5596	110576887
Haemoptysis	37.97	30.09	33	6783	71321	110511162
Glomerular vascular disorder	36.22	30.09	7	6809	230	110582253
Haematotoxicity	36.00	30.09	20	6796	21062	110561421
Anaemia	32.31	30.09	90	6726	546996	110035487
Peripheral sensory neuropathy	31.74	30.09	17	6799	16663	110565820
Neoplasm progression	30.64	30.09	28	6788	64567	110517916

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FG02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors
FDA MoA	N0000020032	VEGFR2 Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D006131	Growth Inhibitors
MeSH PA	D006133	Growth Substances
MeSH PA	D020533	Angiogenesis Inhibitors
FDA EPC	N0000191009	Vascular Endothelial Growth Factor Receptor 2 Antagonist
CHEBI has role	CHEBI:35610	antineoplastic agent

Related Drugs by ATC class:

L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors 1 drug

bevacizumab

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Liver cell carcinoma	indication	109841003	DOID:684
Non-small cell lung cancer	indication	254637007	DOID:3908
Malignant tumor of stomach	indication	363349007	DOID:10534
Adenocarcinoma of stomach	indication	408647009	DOID:3717
Malignant neoplasm of colon and/or rectum	indication	781382000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	ANTIBODY BINDING	Kd	10.30		IUPHAR	DRUG LABEL

External reference:

ID	Source
D99YVK4L0X	UNII
D09371	KEGG_DRUG
4033300	VUID
N0000190752	NUI
4033300	VANDF
C2742502	UMLSCUI
CHEBI:750139	CHEBI
CHEMBL1743062	ChEMBL_ID
DB05578	DRUGBANK_ID
D000096662	MESH_DESCRIPTOR_UI
9098	INN_ID
7390	IUPHAR_LIGAND_ID
1535922	RXNORM
219168	MMSL
30265	MMSL
d08252	MMSL
015502	NDDF
704259004	SNOMEDCT_US
704260009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CYRAMZA	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7669	SOLUTION	10 mg	INTRAVENOUS	BLA	28 sections
CYRAMZA	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7678	SOLUTION	10 mg	INTRAVENOUS	BLA	28 sections